Canal calcique

Crobenetine (BIII 890 CL) Free Base is a selective NaV channel blocker that eliminates VTD-induced [Ca2+] elevation.

R 56865 is a weak potential-operated channel inhibitor that inhibits the late sodium current in human isolated cardiomyocytes.

Upacicalcet (AJT-240) is a calcium mimetic for SHPT in dialysis, reducing PTH by targeting parathyroid receptors.

DS16570511 is a novel, cell-permeable inhibitor targeting the mitochondrial calcium uniporter.

Clopimozide (R-29764), a long-acting oral antischizophrenic, blocks calcium channels and [3H] nilandipine binding.

SERCA2a activator 1 boosts heart function by reducing phospholamban restraint and enhancing cardiac contraction-relaxation cycles.

Budiodarone (ATI-2042) resembles amiodarone, potentially preventing atrial fibrillation.

Mioflazine hydrochloride anhydrous is a nucleoside transport inhibitor that acts on adenosine to improve sleep.

A selective vascular KCa1.1 channel stimulator with CaV1.2 blocking ability and mild myorelaxant effects.

HA-1004 dihydrochloride is an inhibitor of PKA, PKC, cGKI, MYLK, and calcium channel protein

MONIRO-1 blocks T/N-type Ca²⁺ channels: hCav2.2 (IC50: 34μM), hCav3.1 (3.3μM), hCav3.2 (1.7μM), hCav3.3 (7.2μM).

Naltiazem, a calcium channel antagonist, is used potentially for the treatment of arrhythmias, hypertension and myocardial infarction.

Coelenterazine H, a Ca2+ sensitive synthetic derivative, is a luminescent biomolecule used to measure Ca2+ changes.

NKY-722 (HCl), also known as Iganidipine, is a calcium channel blocker potentially for the treatment of glaucoma.

ATI-22-107 is a positive cardiac inotropic agent which may affect myocyte calcium cycling and contractility.

5J-4 is a potent a blocker of calcium release-activated calcium (CRAC) channel and store-operated calcium entry (SOCE).

RO 23-6152, a new calcium antagonist, can inhibit platelet aggregation in vitro associated with occlusive coronary thrombus formation.

Broad spectrum cation channel blocker

Darodipine (PY-108068) is a dihydropyridine type Ca+2 antagonist.

(S)-(-)-Bay-K-8644 ((S)-(-)-Bay K 8644) is an agonist of L-type Ca2+ channel and activates Ba2+ currents with an EC50 of 32 nM.

8-Bromo NAD+ serves as a prodrug for the cyclic ADP-ribose (cADPR) inhibitor, 8-bromo cADPR, undergoing conversion to its active form by the enzyme CD38.

Piprofurol is used as a Calcium channel blocker.

BBT has anti-hyperglycemic activity, protecting beta cells from cytokine or streptozotocin-induced cell death, and restoring beta cell function.

Nelutroctiv is a potent activator of cardiac troponin.

Halofuginone hydrochloride (RU-19110), a derivative of Febrifugine, functions as a competitive inhibitor of prolyl-tRNA synthetase, displaying a Ki value of 18.3 nM. This compound effectively inhibits type-I collagen synthesis, providing therapeutic benefits in osteoarthritis (OA) by impeding TGF-β signaling. Additionally, it serves as a potent pulmonary vasodilator, mainly through the activation of Kv channels and the inhibition of various calcium channels including voltage-gated, receptor-operated, and store-operated ones. Beyond its vascular effects, Halofuginone hydrochloride exhibits a broad spectrum of biological activities, including anti-malarial, anti-inflammatory, anti-cancer, and anti-fibrotic properties, supported by multiple studies.

Iganidipine（NKY 722） is a new water-soluble Ca2+ antagonist with antihypertensive activity for research and neurological related diseases.

RS 5773 is a benzothiazepine derivative with antianginal effects.

TROX-1 is the activation state-dependent Cav2 channel antagonist.

Mioflazine suppresses nucleoside uptake. Mioflazine is an orally active nucleoside transport inhibitor. It has the potential for sleep disorders treatment.

TMDJ-035 is a selective inhibitor of the RyR2 (ryanodine receptor 2).

A 425619 (1-(4-(TRIFLUOROMETHYL)BENZYL)-3-(ISOQUINOLIN-5-YL)UREA) is a potent TRPV1 antagonist

Cavα2δ1&NET-IN-3 (example 216) is an inhibitor targeting both the α2δ subunit of voltage-gated calcium channels (VGCC) and the noradrenaline transporter (NET).

Mioflazine hydrochloride is a nucleoside transport inhibitor that acts on adenosine to improve sleep.

Cav 3.2 Inhibitor 4 (Compound 21) is a selective and potent inhibitor of the T-type calcium channel (Ca v 3.2), demonstrating peripheral restriction with an

N-type calcium channel blocker-1 is an orally active analgesic agent,shows high affinity to functionally block N-type calcium channels.

Cis-22a: selective TRPV6 inhibitor (IC50=0.32μM), halts T47D breast cancer cell growth.

Reldesemtiv (CK-2127107) boosts exercise capacity, targeting fast muscle troponin, EC50 3.4 μM.

EMD57033 activates cardiac troponin C, enhances Ca2+ sensitivity to boost heart contraction.

Fluspirilene is a long-acting antipsychotic for schizophrenia, inhibiting L-type calcium channels (IC50: 0.03 μM).

Bupivacaine hydrochloride monohydrate is an NMDA receptor inhibitor that inhibits SCN5A channels and is commonly used in the study of chronic pain.

Emopamil, a calcium channel inhibitor, reduces neuronal damage caused by ischemia.

Leualacin is a novel calcium blocker from Hapsidospora irregularis.

IAA65 is a potent inhibitor of T-type calcium channels, exhibiting an IC50 value of 18.9 μM, and holds potential for use in epilepsy research [1].

Mibefradil dihydrochloride hydrate is a long-acting antihypertensive blocking high-voltage L calcium channels.

Cav 3.2 inhibitor 3 is a potent inhibitor of the Cav3.2 T-type Ca2+channel (IC50: 0.1534 μM) and has a low binding affinity for D2 receptors.

TTA-P1: potent T-type calcium channel inhibitor; impacts neuron firing, hormone secretion, cell growth; potential in absence epilepsy research.

Cav 3.2 inhibitor 1 targets T-type calcium channels, weakly binds D2 receptors, and aids physical and visceral pain research.